Precious Metals Investing Platform
Case Study · Biopharma
Kemwell Biopharma.
Biologics Development and Manufacturing
Visit live site
Client
Kemwell Biopharma
Year
2025
Project
Growth Marketing
Sector
Biopharma
The brand
About Kemwell Biopharma.
Kemwell Biopharma is a biologics development and manufacturing company that provides innovative solutions for the biopharma industry. The company specializes in the development and manufacturing of biologics, including proteins, peptides, and antibodies.
Capabilities engaged
BiopharmaDigital Marketing
The Challenge
What we
were solving.
Kemwell Biopharma operates in a highly specialised pharmaceutical industry where services are complex and decision making cycles are long. The company aimed to generate qualified B2B leads and increase visibility among global pharmaceutical organisations. Reaching the right stakeholders and improving campaign effectiveness required a focused marketing approach.
- 01Generating qualified leads in a highly regulated and specialised pharmaceutical industry was challenging.
- 02Reaching global decision makers and industry stakeholders required targeted engagement strategies.
- 03Improving campaign performance and lead quality in a niche market was difficult.
Our Approach
01
Discovery, the CDMO buyer journey
A single CDMO qualification can take eighteen months and involve a dozen stakeholders. Marketing in this category does not generate leads in the conventional sense, it builds the conditions under which a pharma sponsor will short-list you in the first place.
Discovery mapped Kemwell's actual buyers, heads of outsourcing, technology-transfer leads, quality and compliance officers, across priority sponsor geographies (US, EU, Japan), and the publications, conferences, and decision moments that mattered to each.
- Sponsor-side stakeholder map across four priority regions
- Audit of trade media, conferences, and analyst voices
- Regulatory-context messaging review with QA
- Twelve-month presence calendar tied to global events
02
Editorial and trade-press strategy
We invested disproportionately in showing up where pharma decision-makers already read: bylined articles in Pharmaceutical Manufacturing, Contract Pharma, BioProcess International, and Outsourcing-Pharma; technical webinars in partnership with sponsor-side leaders; and LinkedIn-led thought leadership from named subject-matter experts.
Every piece was reviewed by Kemwell's QA team before publication. In a category where regulatory imprecision damages credibility, that gating was the brand-safety mechanism, and the differentiator.
- Bylined contributions in four tier-one trade publications
- Technical webinars with named SMEs and sponsor partners
- QA-gated content production pipeline
- LinkedIn thought-leadership programme for senior leaders
03
Conferences as marketing infrastructure
CPHI, BIO, AAPS, and Interphex were treated as the moments where reputations are made, not booth-and-brochure exercises. Each event combined a measured paid presence, a private dinner programme for named accounts, and at least one technical paper or panel position.
Pre-event ABM warmed up the priority sponsor list; on-site engagement focused on quality of conversation over quantity; post-event follow-up was orchestrated through a single sales-enablement workflow.
- Annual presence plan across five global pharma events
- Private dinner programme with priority sponsors
- Speaking and paper submissions at every flagship event
- Pre / at / post-event ABM in one orchestrated workflow
04
Sponsor-facing portal and RFP enablement
By the time a sponsor reaches an RFP, the brand has either already won or already lost. We built a sponsor-facing portal that surfaced live capacity, regulatory inspection history, modality coverage, and reference availability, accelerating qualification stages that traditionally bog down in email back-and-forth.
Sales enablement was rebuilt around modular, source-of-truth-linked materials so every BD interaction reflected current capacity, current pricing, and current case studies.
- Sponsor portal with live capacity and inspection data
- Modular sales decks tied to source-of-truth systems
- Regulatory and modality coverage matrix
- Reference programme with pre-cleared case-study assets
Visual journey
The Result
Outcomes
delivered.
delivered.
“12× increase in inbound RFPs from priority sponsor geographies, alongside a step-change in trade-press authority and conference engagement that re-framed Kemwell's position with global pharma decision-makers.”
What changed
01 · Outcome
Inbound RFPs from Priority Geos
A 12× increase in inbound RFPs from US and EU sponsors over the engagement period, qualified, not vanity, opportunities.
02 · Outcome
Trade-Press Authority
Bylined presence in every tier-one CDMO publication on the priority calendar, compounding into a consistent share-of-voice lead.
03 · Outcome
Conference Engagement
Speaking slots, paper acceptances, and private-dinner attendance across every flagship event, reframing Kemwell's category position in the room.
04 · Outcome
Sales Velocity
Time from sponsor first-contact to qualified RFP shortened materially through the sponsor portal and sales-enablement programme.
Build something like this
Want results
like Kemwell Biopharma's?
Tell us where your brand is now, and where it needs to be. Briefs read by humans, we respond within one business day.
Built for brands
who measure twice.
Your next chapter starts here.